Cellular Biomedicine Group Profit Margin

Cellular Biomedicine Group (CBMG) currently reports a profit margin of -16969.89% as of September 2020. That compares with -61118.98% in the prior-year period — up 72.2% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Cellular Biomedicine Group's profit margin history and peer comparisons.

Cellular Biomedicine Group's profit margin increased from -61118.98% to -16969.89% — a 72.2% year-over-year increase (period ending September 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cellular Biomedicine Group's profit margin of -16969.89% is lower than the Healthcare sector average of 9.48%. That is roughly 179089.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cellular Biomedicine Group's current -16969.89% should be judged against Healthcare norms (sector average: 9.48%) and against CBMG's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -16969.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Cellular Biomedicine Group, and consider following CBMG for alerts when major investors trade the stock.